EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases.
about
BRCAness: finding the Achilles heel in ovarian cancerThe role of PARP in DNA repair and its therapeutic exploitationPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineA quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines.The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY.Blocking the PI3K/AKT pathway enhances mammalian reovirus replication by repressing IFN-stimulated genes.Therapeutic applications of PARP inhibitors: anticancer therapy and beyondInvestigating the human Calcineurin Interaction Network using the πɸLxVP SLiM.The 11q13-q14 amplicon: clinicopathological correlations and potential drivers.Predictive biomarkers for cancer therapy with PARP inhibitors.The function of EMSY in cancer development.The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.EMSY promoted the growth and migration of ovarian cancer cells.Genetics of eosinophilic esophagitis.Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.Functional characterization of EMSY gene amplification in human cancers.Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer.Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer.
P2860
Q24630872-D681559A-CBA4-4DE5-82F2-488F7020DBEAQ27002399-B53B5AD6-4944-4325-9D91-2109B243268EQ28072204-1400172A-BF78-4A17-967A-A853EF2BD692Q35031170-298B59A5-5F61-44E0-9339-F334DD588BB9Q35534509-5F2D828C-0E8A-4D5D-92CA-27D277E52ACCQ35844958-E6A45BCA-5ECA-4194-8C47-377B8E80F415Q36018543-FFF6D472-4028-4EFC-9D20-37AC985055B8Q36853236-098F30B8-6468-45C1-B882-5F9258CC2257Q37504397-AF33052A-AAAC-4E83-970B-4C532408CF12Q38066149-CFBDD7C6-74D3-40F2-9ED0-A4820101646FQ38137764-ECEC612B-8283-4783-8071-F6368043A419Q38194481-F46C211F-7E48-499C-8DB8-7E08E9B30FF4Q38289381-0C0C3341-0F67-4BDB-BA6B-8AD3E39D8A94Q38928376-881F6D23-C26A-4391-B7A9-B4499AD754E8Q39146390-B427A249-7D93-4890-83DA-C150BF508925Q39309080-0FEF7377-4AD4-41A5-86AE-4FDA9F6BE0EBQ39511351-3E8BD2D7-0DBE-4EB3-8216-28356EFC2D7CQ52715788-98DC881B-9878-483D-9A73-7E6412520F41Q55085143-53CAF071-1C65-423E-B196-8550DBA15DC3
P2860
EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
EMSY overexpression disrupts t ...... dromes as checkpoint diseases.
@ast
EMSY overexpression disrupts t ...... dromes as checkpoint diseases.
@en
type
label
EMSY overexpression disrupts t ...... dromes as checkpoint diseases.
@ast
EMSY overexpression disrupts t ...... dromes as checkpoint diseases.
@en
prefLabel
EMSY overexpression disrupts t ...... dromes as checkpoint diseases.
@ast
EMSY overexpression disrupts t ...... dromes as checkpoint diseases.
@en
P2860
P1476
EMSY overexpression disrupts t ...... dromes as checkpoint diseases.
@en
P2093
Abdellah Belmaaza
Isabelle Cousineau
P2860
P2888
P304
P356
10.1007/S00438-011-0612-5
P577
2011-03-16T00:00:00Z